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Abstract Transthyretin (TTR) amyloidoses comprise a wide
spectrum of acquired and hereditary diseases triggered by
extracellular deposition of toxic TTR aggregates in various
organs. Despite recent advances regarding the elucidation of
the molecular mechanisms underlying TTR misfolding and
pathogenic self-assembly, there is still no effective therapy for
treatment of these fatal disorders. Recently, the “molecular
tweezers”, CLR01, has been reported to inhibit self-assembly
and toxicity of different amyloidogenic proteins in vitro, in-
cluding TTR, by interfering with hydrophobic and electrostat-
ic interactions known to play an important role in the aggre-
gation process. In addition, CLR01 showed therapeutic effects
in animal models of Alzheimer’s disease and Parkinson’s
disease. Here, we assessed the ability of CLR01 to modulate
TTR misfolding and aggregation in cell culture and in an
animal model. In cell culture assays we found that CLR01
inhibited TTR oligomerization in the conditioned medium and
alleviated TTR-induced neurotoxicity by redirecting TTR ag-
gregation into the formation of innocuous assemblies. To
determine whether CLR01 was effective in vivo, we tested
the compound in mice expressing TTR V30M, a model of
familial amyloidotic polyneuropathy, which recapitulates the
main pathological features of the human disease. Immunohis-
tochemical and Western blot analyses showed a significant
decrease in TTR burden in the gastrointestinal tract and the
peripheral nervous system in mice treated with CLR01, with a
concomitant reduction in aggregate-induced endoplasmic re-
ticulum stress response, protein oxidation, and apoptosis.
Taken together, our preclinical data suggest that CLR01 is a
promising lead compound for development of innovative,
disease-modifying therapy for TTR amyloidosis.
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Introduction
Transthyretin (TTR) is a 55-kDa tetramer made of identical
subunits of 127 amino acids and contains an extensiveβ-sheet
structure [1]. TTR is synthesized mainly in the liver and the
choroid plexus of the brain, and is secreted to the plasma and
cerebrospinal fluid, respectively. The transport of thyroxine
(T4) and retinol are the two most recognized physiological
functions of TTR. Structurally, TTR has two identical inner T4
binding sites located at the dimer–dimer interface. Although
TTR carries about 15 % of total T4 in the plasma, more than
99 % of the T4-binding sites remain unoccupied [1].
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More than 100 TTR single point mutations have been
reported, most of them associated with abnormal TTR
misfolding and self-assembly into amyloid fibrils that
display distinct patterns of organ involvement, age of
onset, and clinical course. Substitution of methionine for
valine at position 30 of TTR (TTR V30M) results from
the most common mutation associated with familial
amyloidotic polyneuropathy (FAP), a multivisceral and
life-threatening disease affecting predominantly the pe-
ripheral (PNS) and autonomic nervous system [2,3]. FAP
presents a wide geographic distribution, with the largest
populations in Portugal, Japan, and Sweden, and is esti-
mated to affect ∼5000–10,000 patients worldwide [4].
Besides peripheral neuropathy, cardiomyopathy, amy-
loid deposition in the eye, carpal-tunnel syndrome, or
amyloid deposition in the leptomeninges are clinical
phenotypes associated with different forms of TTR am-
yloidosis (amyloidosismutations.com).
Although the involvement of the central nervous system is
unusual, some TTR variants (L12P, D18G, A25T, G53E)
show significant, or even exclusive, central nervous system
pathology, including deposition of mutant TTR within
leptomeningeal vessel walls and pia-arachnoid membranes,
and oculoleptomeningeal amyloidosis [5–8].
In addition, it is important to emphasize that owing to its
high degree of β-sheet structure, wild-type (WT) TTR itself
has an inherent tendency to self-assemble into β-sheet-rich
amyloid fibrils [1]. Thus, a nonhereditary, age-related form of
TTR amyloidosis, senile systemic amyloidosis, is associated
withWTTTR amyloid deposition in the heart, causing cardiac
dysfunction [9].
Proposed therapies for TTR amyloidosis resemble
strategies adopted for other protein misfolding disorders.
Those therapies include i) gene silencing to block syn-
thesis of the protein or its precursor; ii) stabilization of
the native protein structure; iii) modulation of the ag-
gregation pathway; and iv) clearance by disaggregation
of amyloid fibrils [10,11]. Here, we investigated wheth-
er CLR01, a lysine-specific “molecular tweezer” recent-
ly reported to inhibit aggregation and toxicity of multi-
ple disease-related amyloidogenic proteins, including
TTR [12], could modulate TTR assembly and
amyloidogenicity in cell culture and in vivo .
Materials and Methods
Reagents
Epigallocatechin gallate (EGCG) was purchased from Cay-
man Chemicals (Ann Arbor, MI, USA). CLR01 was prepared
and purified as described previously [13,14].
Recombinant TTR
Recombinant TTR Y78F was produced in a bacterial expres-
sion system and purified as described previously [15].
In Vitro Studies of the Effect of CLR01 on Formation of TTR
Aggregates in Cell Culture Medium
Detection of TTR Aggregation in Cell Culture Medium
by a Dot-blot Filter Assay
Experiments were performed as described previously [16]. In
brief, rat Schwannoma cells (RN22, American Type Cell Col-
lection) stably transfected with TTR L55P cDNAwere grown
until 80 % confluence in the absence or presence of 1 μM
CLR01 or EGCG (protein:CLR01, approximately 1:60) in the
cell culture medium for ∼5 days. Then, cells were incubated for
an additional 24 h, still in the presence of the compounds, but
in serum-free media. TTR in the medium was quantified by
enzyme-linked immunosorbent assay (ELISA), and medium
aliquots corresponding to equal amounts of TTR (500 ng) were
blotted onto a 0.2-μm pore cellulose acetate membrane. TTR
aggregates retained on the membrane were immunodetected
using rabbit anti-human TTR antibody (Dako, Glostrup, Den-
mark; 1:500) followed by anti-rabbit horseradish peroxidase
antibody (1:1500) and enhanced chemiluminescence visuali-
zation (GEHealthcare, Buckinghamshire, UK). Dot-blots were
quantified using the Bio-Rad ChemiDoc XRS system with
Image Lab software (Bio-Rad, Hercules, CA, USA). Experi-
ments were repeated at least 3 times and samples were ana-
lyzed in triplicate. All values are expressed as mean ± SD.
Evaluation of Cell Toxicity Induced by TTR Assemblies
and its Inhibition
Rat Schwannoma cells (RN22) were propagated and main-
tained as described previously [16]. Briefly, 80 % confluent
cells in Dulbecco’s minimal essential medium supplemented
with 1 % fetal bovine serum were exposed, for 24 h, to 2 μM
of TTR Y78F oligomers alone (control) or oligomers
pretreated with EGCG (20 μM) or CLR01 (0.2–200.0 μM)
at 37 °C for 6 days. EGCG or CLR01 in the absence of TTR
Y78F were used to test whether the compounds were toxic at
the concentrations used. After the treatment, cells were
trypsinized and lysed using ice-cold lysis buffer containing
5 mM ethylenediaminetetraacetic acid, 2 mM ethylene glycol
tetraacetic acid, 20 mM 3-(N-morpholino) propanesulfonic
acid , 1 % Triton X-100, 1 mM phenylmethanesulfonyl fluo-
ride, and a protease inhibitor mix (GE Healthcare). Cell ly-
sates were used for determination of caspase-3 activation
using the CaspACE fluorimetric 96-well plate assay system
(Sigma-Aldrich, St. Louis, MO, USA). Protein concentration
Molecular Tweezers Targeting Transthyretin Amyloidosis 451
in lysates was determined using a Bio-Rad protein assay kit.
Results are presented as normalized density ± SD.
In Vivo Studies Using a FAP Mouse Model
Ethics Statement
All the experiments described herein were approved by the
Portuguese General Veterinarian Board (authorization number
024976 from DGV-Portugal) and are in compliance with
national rules and the European Communities Council Direc-
tive (86/609/EEC) for the care and handling of laboratory
animals.
Transgenic Mice
Mice expressing human TTR V30M on a TTR-null back-
ground and heterozygous for the heat shock transcription
factor 1 (HSF1), labeled hTTR V30M/HSF [17], were used
for all in vivo experiments. Two groups of 4-month-old ani-
mals were used: animals treated with CLR01 (n=14) or with
vehicle (saline, n=12) administered using subcutaneous os-
motic minipumps (model 1004; Alzet, Cupertino, CA, USA).
Following anesthesia with ketamine/medetomidine, the
pumps were surgically implanted on the dorsal back of mice.
The compound was delivered at a dose of 1.2 mg/kg/day for
35 days. After the treatment, mice were sacrificed and tissues,
specifically, whole gastrointestinal (GI) tract, including stom-
ach, colon, and duodenum, and dorsal root ganglia (DRG)
were immediately excised and frozen at –70º C, or fixed in
4 % neutral buffered formalin and embedded in paraffin for
light microscopy analysis.
Determination of TTR Concentration Levels in Mouse Plasma
by ELISA
TTR plasma concentrations were determined by ELISA,
as described previously [18]. Briefly, 96-well plates
were coated overnight at 4 °C with rabbit anti-human
TTR polyclonal antibody (Abcam, Cambridge, UK).
After blocking and washes, TTR standards (2–25 ng/ml)
and diluted mouse plasma samples were applied in
triplicate and incubated for 2 h at room temperature.
Next, sheep anti-human TTR polyclonal antibody
(Abcam) was added and incubated for 1 h. After wash-
ing, the plate was incubated with anti-sheep antibody-
conjugated alkaline phosphatase. p-Nitrophenyl phos-
phate was employed for color development. The absor-
bance was measured at 405 nm and data were fitted to
a second-order polynomial (quadratic equation).
Analysis of Competition of CLR01 with T4 for the Binding
to Plasma TTR by Native Gel Electrophoresis
Five-microliter aliquots of plasma from mice treated with
vehicle or CLR01 were incubated with [125I]-T4 (specific
radioactivity 1250 μCi/μg; Perkin-Elmer, Waltham, MA,
USA). Then, plasma proteins were fractionated by native
polyacrylamide gel electrophoresis (PAGE), as described pre-
viously [19]. The gel was dried, subjected to phosphor imag-
ing (Typhoon 8600; Molecular Diagnostics, Amersham Bio-
sciences, Uppsala, Sweden), and the intensity of the bands
determined using ImageQuant v. 5.1.
Isoelectric Focusing Under Partially Dissociating Conditions
Twenty-five microliters of plasma from CLR01- and vehicle-
treated mice were subjected to native PAGE. The TTR gel
band in each lane was excised and used for a pH 4.0–6.5
isoelectric focusing (IEF) polyacrylamide gel run for 6 h at
1200 V under partially dissociating conditions (4 M urea)
[19]. Proteins were stained with Coomassie Blue. The gels
were scanned and analyzed by densitometry using
ImageQuant v. 5.1.
Immunohistochemistry
Five-mm-thick tissue sections were deparaffinated in
Histoclear and hydrated in a descending alcohol concentration
series. Endogenous peroxidase activity was quenched with
3 % hydrogen peroxide in methanol, and sections were
blocked in 4 % fetal bovine serum and 1 % bovine serum
albumin in phosphate-buffered saline. The primary antibodies
and the respective dilutions used were as follows: rabbit
polyclonal anti-TTR (1:1000) (Dako); goat polyclonal anti-
binding immunoglobulin protein (BiP) (1:50) and rabbit poly-
clonal anti-Fas (1:200) (Santa Cruz Biotechnology, Santa
Cruz, CA, USA); rabbit polyclonal anti-3-nitrotyrosine
(1:500) (Chemicon, Temecula, CA, USA). Antibodies were
diluted in blocking solution and incubated overnight at 4 °C.
Slides were subsequently incubated with a biotin–extravidin
enzyme complex (ABC Elite Vectastain kit; Vector Laborato-
ries, Burlingame, CA, USA) using hydrogen peroxide and
diaminobenzidine as substrate and chromogen, respectively.
Immunohistochemistry (IHC) analysis was carried out inde-
pendently by two investigators blinded to the origin of the
tested tissue sections. Semi-quantitative immunohistochemi-
cal analysis was performed using Image-Pro Plus v. 5.1. Each
slide was analyzed in 5 different representative areas.
Western Blot Analysis
Disease-relevant tissues, including DRG, stomach, and colon,
were homogenized on ice using a small glass rod homogenizer
452 Ferreira et al.
in lysis buffer (as in the section ‘Evaluation of Cell Toxicity
Induced by TTR Assemblies and its Inhibition’). After centri-
fugation at 18,700 g for 20 mins at 4 °C, protein concentration
in the supernatant was determined by the Bradford protein
assay (Bio-Rad). Fifty micrograms of total protein from each
tissue sample was fractionated on 15 % sodium dodecyl
sulfate-PAGE and transferred onto nitrocellulose Hybond-C
membranes using the Mini Trans-Blot Cell (Bio-Rad) system.
The primary antibodies and the respective dilutions used were
as follows: rabbit polyclonal anti-TTR (1:1000; Dako,
Carpinteria, CA, USA); rabbit polyclonal anti-BiP (1:1000)
(Abcam); mouse monoclonal anti-glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) (1:1000) (Abcam). Blots
were visualized using enhanced chemiluminescence
(Amersham ECL Prime) and quantified as described in ‘De-
tection of TTRAggregation in Cell CultureMedium by a Dot-
blot Filter Assay’. Immunosignals were normalized to
GAPDH expression. Each group was compared with control.
Results are presented as normalized density ± SD. A p-value<
0.05 was considered statistically significant.
Results
CLR01 Inhibits TTR Aggregation in a Cell Culture System
The effect of CLR01 on TTR aggregation was investigated in
a rat Schwannoma cell line (RN22) transfected with TTR
L55P, which secretes the TTR variant to the medium where
it aggregates [16]. The cells were grown in the absence or
presence of CLR01 or of EGCG, which has previously been
found to be a potent inhibitor of TTR aggregation [20,21].
Then, cell culture media aliquots were spotted on a cellulose–
acetate membrane, which retains TTR aggregates, but not
soluble TTR. The membranes were probed with an anti-TTR
antibody. The results are shown in Fig. 1.
In agreement with previous studies [20,21] dot-blot of
conditioned medium obtained in the presence of EGCG re-
vealed almost complete inhibition of TTR aggregation (88.74
±7.41%, p<0.001). Similarly, conditioned medium from cells
incubated in the presence of CLR01 presented significantly
fewer aggregates than media from control cells (80.50 %±
17.10, p<0.001).
CLR01 Protects Neuronal Cells Against TTR-induced
Toxicity
To investigate the impact of CLR01 on the toxicity of TTR
assemblies we performed a standardized caspase-3 assay in
RN22 cells exposed to TTR oligomers formed in the absence
or presence of CLR01, or EGCG as a positive control. Cells
were exposed to TTRY78F oligomers pretreated for 24 h with
EGCG or CLR01, or with TTR incubated in the absence of
inhibitors as a negative control. Different concentrations of
CLR01 were tested, and the toxicity of CLR01 and EGCG at
the same concentration in the absence of TTR was also
assayed.
As expected [21], pretreatment of TTR Y78F oligomers
with EGCG resulted in strong inhibition of caspase-3 activa-
tion (16.86 %±5.75 % of the control activity) (Fig. 2). Pre-
incubation of TTRY78F with CLR01 also protected the cells
against the toxicity of the TTR oligomers in a concentration-
dependent manner, decreasing caspase-3 activity to a mini-
mum of 22.17 %±12.20 relative to control at 200 μM (TTR:
CLR01 concentration ratio 1:100; Fig. 2). Thus, CLR01 was
found to be about 1 order of magnitude less potent inhibitor of
TTR oligomer-induced cytotoxicity when compared with
EGCG in this particular cell culture system.
Evaluation of CLR01 Effect in a Mouse Model of FAP
In view of the promising in vitro results described above, we
investigated the effect of peripherally administered CLR01 on
the deposition of TTR and associated biomarkers using a FAP
mouse model expressing the amyloidogenic human TTR
V30M variant on a HSF1-null background [17]. The lack of
HSF1 expression leads to an extensive and early deposition of
nonfibrillar TTR in different organs, including the GI tract and
the PNS. TTR aggregates start to deposit at 3 months of age
and evolve to fibrillar, congophilic material typically by 1 year
of age. Therefore, this mouse model is highly relevant to
testing new therapeutic strategies targeting different stages of
the disease. In this study, we aimed at evaluating the effect of
CLR01 at a very early stage of the disease in which deposition
of nonfibrillar TTR occurs in different tissues.
Four-month-old hTTR V30M/HSF mice were treated for
35 days with CLR01 (1.2 mg/kg/day) in saline as vehicle (n=
14) or vehicle alone (n=12) using subcutaneously implanted
osmotic minipumps. Protocol design, drug dosage, and selec-
tion of endpoints were based on previous studies [22,23]. The
CLR01 dosage used in this study was not expected to cause
adverse side effects based on previous studies [23]. Indeed, no
difference was observed in body weight or mortality between
animals treated with CLR01 and age-matched vehicle-treated
controls (Supplementary Table 1). In addition, no histological
abnormalities were observed in liver sections stained with
hematoxylin and eosin for morphologic assessment.
CLR01 Does not Interfere With the Transport of T4
by the Thyroid Hormone Serum Transport Proteins
To assess if CLR01 interacts with TTR at the T4 binding site
in vivo, plasma from mice treated with CLR01 or vehicle was
incubated with radiolabeled T4 (
125I-T4) and subjected to gel
electrophoresis under native conditions. T4-binding proteins
were visualized by phosphor imaging analysis, as shown in
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Supplementary Fig. S1.A. Twomain T4 binding proteins were
detected corresponding to albumin (the main mouse plasma
T4 binding protein) and TTR. Binding of T4 to T4-binding
globulin in mouse plasma was only residual. The results
showed that the relative intensity of the protein bands from
treated and untreated mice was similar in both cases (Supple-
mentary Fig. S1.B), indicating that CLR01 did not bind to
TTR at the T4 binding sites.
CLR01 Does not Impact the Native TTR Tetramer Stability
IEF, under partially dissociating conditions (4 M urea), allows
visualization of different plasma TTR species, including
monomer, an oxidized monomer, and several lower-pI bands
corresponding to tetramers. Stabilization of the native TTR
conformation by small molecules has been associated with
higher tetramer/total protein ratios [19]. Densitometry analysis
of the IEF gels demonstrated that CLR01 treatment did not
increase plasma TTR resistance to dissociation when com-
pared with plasma TTR from control animals under the tested
conditions (Supplementary Fig. S2.A, B).
CLR01 Reduces Extracellular TTR Deposition and Rescues
Tissue Damage Without Adverse Effects
TTR levels in plasma from vehicle-treated and CLR01-treated
mice were determined by ELISA and showed no statistical
difference between the two groups (504±123 μg TTR/ml and
Fig. 1 CLR01 inhibits transthyretin (TTR) aggregation in a cell culture
system. (A) Immunodetection of TTR oligomers in a dot-blot filtration
assay of conditioned medium from TTR L55P-transfected Schwannoma
RN22 cells grown in the absence (control) or in the presence of CLR01 or
epigallocatechin gallate (EGCG). (B) Densitometric analysis of the dot-
blot assay showing the percentage of inhibition of aggregate formation by
each compound, compared with the control (0 % inhibition)
(***p<0.005)
Fig. 2 CLR01 inhibits
transthyretin (TTR)-induced
toxicity in a-dose dependent
manner. Activation of caspase-3
in Schwannoma RN22 cells




(20 μM) or CLR01 (0.2–
200.0 μM) for 24 h. In parallel,
cells were incubated with EGCG
or CLR01 alone, at the same
concentrations (**p<0.01;
***p<0.005). NS=nonsignificant
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560±136 μg TTR/ml, respectively), suggesting that CLR01
treatment did not affect TTR turnover in vivo.
To address the efficacy of CLR01 in preventing TTR
deposition and tissue damage, several tissues were analyzed
by IHC or Western blot to evaluate the levels of TTR burden
and associated biomarkers. At the end of the treatment, the
mice were ∼5.5 months old. As expected at this age, vehicle-
treated mice presented extensive TTR staining throughout the
interstitial connective tissue of several organs, with particular
involvement of the PNS. In the DRG, TTR aggregates were
found extracellularly surrounding the perikaryon in close con-
tact with the satellite glial cells. These observations were in
agreement with previous reports [17], and simulate the path-
ological findings of FAP.
In contrast, after 5 weeks of subcutaneous administration of
CLR01, hTTR V30M/HSF mice showed a significant reduc-
tion of TTR deposition in all target organs analyzed by IHC:
33 % in stomach (% occupied area: controls 17.79 %±6.18 %
vsCLR01-treated 11.84%±5.27%, p<0.01; Fig. 3A), 51% in
colon (controls 8.53 %±4.13 %, CLR01-treated 4.22±3.00,
p<0.01; Fig. 4A), and 47 % in DRG (controls 10.76 %±
3.87 %, CLR01-treated 5.74 %±3.81 %, p<0.01; Fig. 5A).
These results were further supported by Western blot analysis
of TTR in whole-tissue extracts (Figs 3B, 4B, and 5B,
respectively).
Accumulation of amyloidogenic proteins, such as
TTR, in the extracellular space leads to membrane per-
meabilization. Consequently, perturbation of intracellular
calcium homeostasis has been proposed as a common
primary pathogenic event responsible for initiating sev-
eral pathogenic signaling pathways in many amyloid-
related disorders [24]. To investigate if inhibition of
extracellular deposition of TTR in CLR01-treated mice
reduced TTR-induced tissue injury, we analyzed tissues
for activation of several disease markers, including en-
doplasmic reticulum–BiP, the Fas/CD95 death receptor,
and 3-nitrotyrosine [25–27].
Compared with vehicle-treated mice, we found a 34 %
reduction in the BiP-stained area of the stomach of CLR01-
treated mice (% occupied area: controls 14.25 %±6.46 % vs
CLR01-treated 9.43±5.05, p<0.05; Fig. 3A) and an even
higher decrease in colon (67 %; controls 3.78±2.10,
CLR01-treated 1.26±2.00, p<0.01; Fig. 4A) and DRG
(63 %; controls 11.69 %±4.85 %, CLR01-treated 4.31 %±
1.05 %, p<0.001; Fig. 5A). Western blot evaluation of BiP
levels revealed a similar trend, as shown in Figs 3B, 4B and
5B, respectively.
We next evaluated Fas/CD95 death receptor immunostain-
ing and found a significant decrease in Fas-mediated apoptosis
in CLR01-treated mice compared with the vehicle-treated
group in stomach (39 % reduction, p<0.001; Fig. 3A), colon
(56 % reduction, p<0.001; Fig. 4A), and DRG (68 % reduc-
tion, p<0.001; Fig. 5A).
TTR-induced cytotoxicity also was addressed by analysis
of 3-nitrotyrosine, one of the most common products of tyro-
sine nitration mediated by reactive nitrogen species. The re-
sults showed a strong decrease in nitric oxide-dependent
oxidative stress throughout the GI tract in CLR01-treatedmice
relative to vehicle-treated mice [stomach: 78 % reduction,
p<0.001 (Fig. 3A); colon: 76 % reduction, p<0.001
(Fig. 4A] and DRG (68 % reduction, p<0.001; Fig. 5A).
Discussion
Over the last few years, many small compounds have been
proposed as disease-modifying therapeutic agents specific for
TTR-related amyloidosis. Among those, Tafamidis, a kinetic
stabilizer of TTR dissociation, has completed phase II/III trials
for the treatment of FAP.
However, different compounds may be needed for effective
stabilization of different TTR mutants and, in this sense, more
recently, several nonspecific amyloid inhibitors have been
reported, as is the case of EGCG [20–22]. Similarly, CLR01
was found to be an efficient inhibitor of aggregation of 9
different amyloidogenic proteins, in vitro, one of which was
TTR [12].
Here, we extended the examination of CLR01 as a poten-
tial disease-modifying agent for TTR-related amyloidosis,
first by comparing its effect side-by-side with EGCG in vitro.
The two compounds were tested for their capability in mod-
ulating TTR abnormal folding and toxicity in neuronal culture
systems. We found that CLR01 strongly suppressed TTR
aggregation and alleviated cultured cells from the neurotoxic
effect induced by extracellular oligomeric TTR in a dose-
dependent manner. Because CLR01 has been shown to bind
to amyloidogenic proteins already at the monomer stage [12],
we hypothesize that it remodels early, partially unfolded TTR
monomers and/or oligomers into nontoxic species and pre-
vents their aggregation. In addition, CLR01may interfere with
the interaction of TTR assemblies with membrane targets.
In both the inhibition of self-assembly (Fig. 1) and inhibi-
tion of toxicity (Fig. 2) assays, EGCGwas more effective than
CLR01, though this effect was substantially more pronounced
in the caspase-inhibition assay. A likely explanation is the
longer incubation time used in that assay relative to the ag-
gregation inhibition assay. Recently, Palhano et al. [28]
showed that EGCG binds covalently to the target protein,
and this reaction reaches completion within several hours.
Therefore, by the time the protein–inhibitor mixture was
added to the cell culture, essentially all of the TTRwas already
covalently modified by EGCG. In contrast, CLR01 binds
noncovalently and its binding is highly labile [29]. Thus, the
different nature of the interaction of the 2 compounds with
TTR might be responsible for the difference of inhibition
efficiency under the conditions of the assay as 10-times higher
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concentrations of CLR01 were required to achieve the same
level of inhibition found for EGCG (Fig. 2). Similarly to the
results observed here, Sinha et al. [30] found that CLR01 and
EGCG had an analogous inhibitory effect on Aβ self-
assembly, yet EGCG was more effective than CLR01 in
preventing Aβ-induced toxicity in several culture systems,
likely owing to the differences in mechanism of action
described above. In addition, it is possible that the ability of
EGCG to modulate multiple signaling pathways associated
with neurodegeneration [31,32] and to scavenge free radicals
[32] provided additional neuroprotective activities, which are
not shared by CLR01.
Considering the chemical structure of CLR01 and EGCG,
they share little structural similarities and apparently act
Fig. 3 CLR01 decreases transthyretin (TTR) burden and associated tox-
icity in the stomach of heat-shock transcription factor (HSF)-1–TTR
V30M/HSF mice. (A) Representative immunohistochemistry analysis of
TTR, binding immunoglobulin protein (BiP), Fas, and 3-nitrotyrosine in
stomach of mice treated with CLR01 (right panels; n=14) and age-matched
controls (left panels; n=12); 20× magnification. Bar graphs: quantification
of immunohistochemical images is represented as percentage of occupied
area ± SD (**p<0.01; ***p<0.005). (B) Representative anti-BiP and anti-
TTRWestern blots of stomachs fromCLR01- and vehicle-treatedmice. Bar
graphs: normalized BiP/glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) and TTR/GAPDH density quantifications ± SD (*p<0.05;
**p<0.01)
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through distinct mechanisms. CLR01 binds specifically
to exposed lysine residues with μM affinity and with
lower affinity to arginines (Fig. 6A, B). In contrast,
EGCG has been reported to interact nonspecifically with
amyloidogenic proteins through hydrophobic interactions
and hydrogen bonding, and to not bind monomers to a
significant extent [33,34], likely because its binding
sites are grooves in the β-sheet structure that are
characteristic of amyloids and “fibrillar oligomers”.
However, recently, EGCG was also reported to bind
covalently to cysteinyl thiol residues, and to free amines
of the N-terminus or of lysine side chains through auto-
oxidation [28]. Thus, even though both compounds can
bind to lysine residues, CLR01 binds reversibly, regard-
less of assembly state, whereas EGCG binds to larger
assemblies and attaches to them irreversibly.
Fig. 4 CLR01 decreases transthyretin (TTR) burden and associated
toxicity in colon of hTTRV30M/HSF mice. (A) Illustrative immunohis-
tochemistry analysis of TTR, binding immunoglobulin protein (BiP), Fas,
and 3-nitrotyrosine in colon of mice treated with CLR01 (right panels; n=
14) and age-matched controls (left panels; n=12); 20× magnification. Bar
graph: quantification of immunohistochemical images is presented as
percentage of occupied area ± SD (**p<0.01; ***p<0.005). (B) Repre-
sentative anti-BiP and anti-TTRWestern blots of colon from CLR01- and
vehicle-treated mice. Bar graph: normalized BiP/GAPDH and TTR/
GAPDH density quantifications ± SD (*p<0.05; **p<0.01)
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In view of the in vitro results described above and recent
studies showing a therapeutic effect for CLR01 in animal
models of Alzheimer’s disease (AD) [23] and Parkinson’s
disease [35], we examined the impact of CLR01 on patho-
genic TTR deposition in a mouse model of FAP [17] at early
stages of disease.
In this study, we assessed the effect of CLR01 on TTR
deposition throughout the GI tract and the PNS, and found a
significant decrease of TTR burden in all the organs analyzed,
particularly in the intestine, stomach, and DRG. These results
were further supported by a substantial decrease of TTR
deposition-associated endoplasmic reticulum stress response,
Fig. 5 CLR01 decreases transthyretin (TTR) burden and associat-
ed toxicity in dorsal root ganglia (DRG) of hTTR V30M/HSF
mice. (A) Representative immunohistochemistry analysis of TTR,
binding immunoglobulin protein (BiP), Fas, and 3-nitrotyrosine in
DRG of mice treated with CLR01 (right panels; n=14) and age-
matched controls (left panels; n=12); 20× magnification. Bar
graph: quantification of immunohistochemical images is presented
as percentage of occupied area ± SD (**p<0.01; ***p<0.005).
(B) Representative anti-BiP and anti-TTR Western blots of DRG
from CLR01- and vehicle-treated mice. Bar graph: normalized
BiP/GAPDH and TTR/GAPDH density quantifications ± SD
(**p<0.01)
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apoptosis, and protein oxidation, indicating that reduction of
TTR load by CLR01 correlates with decreased proteotoxicity.
In FAP, neuropathy begins at the earliest stages of the disease
when nonfibrillar TTR deposits in the PNS. Analysis of nerve
biopsy samples from asymptomatic FAP patients showed
upregulation of pro-inflammatory cytokines, extracellular ma-
trix remodeling mediators, and inducible nitric oxide synthase
[25,36]. These pathogenic responses to toxic TTR species are
similar to those observed in other neurodegenerative diseases.
For example, oligomeric β-amyloid (Aβ) induces a potent
inflammatory response, which suppresses microglial phago-
cytosis and uptake of Aβ fibrils, thereby contributing to early
neurodegeneration of AD pathology [37]. Our data clearly
indicate that CLR01 rescues FAP mice from neuronal injury
caused by abnormal protein deposition, similarly to previous-
ly reported data in an AD mouse model [23]. Therefore, it
seems reasonable to speculate that following CLR01 treat-
ment, a restored extracellular environment might improve
TTR clearance by the innate immune system. Supporting this
speculation, in a zebrafish model expressing human, WT α-
synuclein, inhibition of the 26S ubiquitin–proteasome system
by oligomeric or aggregated α-synuclein was alleviated by
treatment with CLR01, leading to a marked reversal of α-
synuclein accumulation [35].
Though we did not compare the effects of CLR01 and
EGCG side-by-side in vivo, it is interesting to compare the
data obtained here to a previous study of EGCG in hTTR
V30M/HSF mice of the same age [22]. Direct comparison is
not possible because the 2 compounds were administered
through different routes and at different doses [22,23]. Neither
compound affected TTR plasma concentration levels, but
EGCG appeared to increase TTR tetramer levels, whereas
CLR01 did not. On average, the effect of EGCG on TTR
deposition and on the levels of the associated biomarkers, BiP,
Fas/CD95, and 3-nitrotyrosine, was moderately larger than
that of CLR01. At the doses administered, EGCG and
CLR01 are expected to reach plasma steady-state levels of
280 nM [38] and 170 nM [23], respectively. Thus, given the
lower dose and shorter treatment period of CLR01, we con-
clude that the impact of the two compounds on FAP pathology
in this mouse model is similar, despite their different mecha-
nisms of action.
Lysine residues are known to play a key role in the aberrant
self-association of many amyloidogenic proteins and have
been involved in anchoring/insertion of amyloid intermedi-
aries to membranes through electrostatic interaction with the
negatively charged phosphate groups of phospholipids
[39–41]. Therefore, exposed lysine residues have been pro-
posed as attractive molecular targets for the development of
new drugs for the prevention/treatment of amyloidosis
[12, 42].
TTR has 8 lysine residues in each of the 4 monomers
comprising the active tetramer (Fig. 6C). All of them are
exposed to the solvent, either on the external surfaces of the
Fig. 6 (A) Chemical structure of
epigallocatechin gallate (EGCG)
and (B) CLR01 complexed with
lysine. (C) Crystal structure of
transthyretin [PDB 2H4E]
highlighting the lysine residues in
one of the monomers. Each
monomer has a β-sandwich
structure composed of two β-
sheets (DAGH and CBEF) and a
short helix. Lys9 and Lys126 are
located in the disordered N- and
C-terminus (not shown)
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β-sandwich arrangement of the monomer (Lys 15 at the
DAGH sheet, and Lys 35, 48, and 70 at the CBEF sheet) or
positioned at the exposed α-helix (Lys 76 and Lys 80) and N-
and C-terminus (Lys 9, Lys 126). Thus, in principle, all
lysine residues can bind to compounds such as CLR01,
and it is conceivable that binding to the Lys located in
the penultimate β-strands (especially Lys 15) would in-
hibit end-to-end alignment of the non-native monomers
and interfere with lateral alignment of protofilaments in
the tight assembly characteristic of amyloid formation.
Precise determination of the binding sites(s) of CLR01
on TTR will require additional investigation.
Despite many recent advances, prevention of, or treatment
for, TTR-related amyloidosis is highly complex and likely will
require diverse approaches. Combination therapies acting si-
multaneously on different molecular targets might increase
treatment effectiveness and improve clinical outcome. This
study demonstrates that CLR01 modulates early stages of
TTR self-assembly and inhibits TTR-induced neurotoxicity.
Our preclinical data support previous studies showing the ben-
eficial effects of CLR01 administration in AD and Parkinson’s
disease-like pathology in vivo, and highlight CLR01 as a broad,
process-specific inhibitor of amyloid formation. Compound
formulation is expected to improve its pharmacological prop-
erties towards potential clinical usefulness.
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